DAVID URRATE: Open Payments
NPI 1598872871 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,232 in 234 payments from 16 companies in 2025. Trend: 2023 $2,959 · 2024 $2,958 · 2025 $3,232
Food & beverage: $3,218Education: $14
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 38 | $647 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 37 | $587 |
| Otsuka America Pharmaceutical, Inc. | 19 | $347 |
| ABBVIE INC. | 21 | $257 |
| Axsome Therapeutics, Inc. | 21 | $253 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $240 |
| Collegium Pharmaceutical, Inc. | 18 | $180 |
| Neurocrine BioSciences, Inc. | 18 | $179 |
| Janssen Pharmaceuticals, Inc | 20 | $141 |
| Lundbeck LLC | 6 | $113 |
Products named: ARISTADA, CAPLYTA, REXULTI, VRAYLAR, TRINTELLIX, Auvelity, Jornay PM, INGREZZA.
Industry payments across TX — which companies pay providers there.
